NDRA
ENDRA Life Sciences Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$4.75
+0.21%Oct 1, 2026, 21:23 UTC
ENDRA Life Sciences amended its Agreement and Plan of Merger with ASP Isotopes, Noble Africa and Renergen, revising the minimum cash closing condition to $3,800,002.59 and increasing Renergen's borrowing capacity under the ASPI Term Loan Facility from $80 million to up to $200 million.
Oct 1, 2026, 21:23 UTC
ENDRA Life Sciences amended a common stock purchase warrant held by LHE LNG Holdings to remove the 4.99% beneficial ownership limitation, with exercise conditional on stockholder approval.
Aug 17, 2026, 12:00 UTC
ENDRA Life Sciences Inc. reported its financial results for the second quarter ended June 30, 2026.
Source:Aug 17, 2026, 00:00 UTC
ENDRA Life Sciences Inc. completed a private placement raising gross proceeds of $50 million, with net proceeds of $3.8 million.
Jul 21, 2026, 22:05 UTC
ASP Isotopes plans to create a publicly listed helium and LNG platform through Noble Africa.
Source:Jul 21, 2026, 22:05 UTC
ASP Isotopes proposed a merger with ENDRA Life Sciences.
Source:Jun 25, 2026, 13:30 UTC
ASP Isotopes announces a proposed merger of Noble Africa with ENDRA Life Sciences, which would establish Noble Africa as a Nasdaq-listed helium platform for Renergen's Virginia Gas Project.